CancerDrs

Lymphoma clinical trials in New Mexico

7 actively recruiting lymphoma trials at 4 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • Memorial Medical Center-Las Cruces — Las Cruces, New Mexico
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in New Mexico:
  • Presbyterian Hospital — Albuquerque, New Mexico
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …

Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in New Mexico:
  • Christus St Vincent Regional Cancer Center — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT ID: NCT04920617
Sites in New Mexico:
  • Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Mexico:
  • Presbyterian Kaseman Hospital (site 208) — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Mexico:
  • Massive Bio SYNERGY-AI site — Albuquerque, New Mexico
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10